Multiple factors are involved in tumor progression, and numerous recent studies have implicated lncRNAs as critical regulators of these processes. In the present study, we identified a NSCLC metastasis-associated lncRNA LINC01234, which is highly expressed in metastatic NSCLC tissues and significantly associated with shorter survival time. In addition, modulation of LINC01234 expression revealed its oncogenic activity through promotion of cell migration, invasion, supporting a potential role for LINC01234 dysregulation in NSCLC progression. Indeed, complementary in vivo studies using a mouse model revealed that LINC01234 plays a key role in tumor metastasis.
A great number of recent studies have demonstrated that lncRNAs contribute to cancer progression through numerous mechanisms; for example, by recruiting histone modification enzymes (such as EZH2, SUZ12, and LSD1) that repress or activate gene transcription [
15,
16] acting as competing endogenous RNAs (ceRNAs) or sponges to inhibit microRNA (miRNA) activity [
11], interacting with RNA-binding proteins (e.g., STAU1, UPF1, and hnRNPL) to regulate mRNA stability [
10,
17,
18] and encoding small active peptide [
19]. In the present study, we investigated the molecular mechanisms through which LINC01234 regulated the tumor progression-related behavior of NSCLC cells, and found that LINC01234 interacted with several RNA-binding proteins, including Ago2, EZH2, LSD1 and SUZ12. Accumulating evidence has revealed the existence of a widespread ceRNA interaction network in which lncRNAs compete with miRNAs for binding sites in the 3′-UTR of target mRNAs. For example, HOXA11-AS promotes gastric cancer cell growth by functioning as a ceRNA for miR-1297 [
16], while HOXD-AS1 acts as a ceRNA for miR-130a-3p and facilitates liver cancer metastasis by regulating SOX4 [
20]. Here, we showed that LINC01234 is a ceRNA for miR-340-5p and miR-27b-3p and antagonizes their repression of VAV3 protein translation in NSCLC cells. MiR-340 and miR-27b have been reported to have tumor-suppressive functions in multiple cancers. For instance, Li et al. reported that miR-340 inhibits ovarian cancer metastasis via inactivation of NF-x03BA;B1 [
21]. Yan et al. found that miRNA-340 inhibits the invasion of esophageal cancer by targeting phosphoserine aminotransferase 1 [
22]. MiR-27b has also been shown to inhibit gastric cancer metastasis by targeting NR2F2 [
23], and suppress NSCLC invasion by targeting SP1 [
24]. In addition to these findings, our results showed that overexpression of miRNA-340 and miR-27b repressed NSCLC cell invasion by targeting VAV3 expression. The VAV family of guanine nucleotide exchange factors participates in numerous important pathological processes, including oncogenesis and cell transformation. Recent studies showed that VAV3 expression is increased in breast, prostate, and colorectal cancer [
25‐
27], and VAV3 promoted cell metastasis in gastric cancer [
28]. Consistent with this, we also found that VAV3 was upregulated in NSCLC, and its knockdown inhibited NSCLC cell invasion. These findings suggest that the LINC01234–miR-340-5p/miR-27b-3p–VAV3 axis plays important roles in the progression of NSCLC.
Our data showed that, in addition to functioning as a ceRNA in the cytoplasm, LINC01234 interacts with some well-known histone modification enzymes, such as EZH2, SUZ12, and LSD1, to repress target gene expression (BTG2) in the nucleus. EZH2 and SUZ12 are core subunits of the Polycomb repressive complex 2 (PRC2), which suppresses gene transcription by trimethylating H3K27. In human melanoma cells, loss of EZH2 partially interfered with invasion capacity [
29]. LSD1, one of the first discovered protein lysine demethylases, demethylates H3K4me2 to H3K4me1 or H3K4me0 [
30]. LSD1 has been found to contribute to invasion and metastasis of luminal breast cancer cells [
31]. We propose that LINC01234 acts as a scaffold and recruits EZH2 and LSD1 to the promoter regions of BTG2, thereby repressing its transcription in NSCLC cells. BTG2 is a newly identified tumor suppressor that belongs to the BTG/TOB family, and many studies have revealed that BTG2 is downregulated in various cancers, including breast cancer, osteosarcoma, and bladder cancer. BTG2 inhibited the hepatocellular carcinoma cell invasion and metastasis [
32‐
34]. Our data show that BTG2 expression is reduced in NSCLC tissues compared with normal lung tissues, and is associated with shorter patient survival. In NSCLC, overexpression of BTG2 inhibited cell invasion, and rescue experiments confirmed that the oncogenic function of LINC01234 is partly dependent on repression of BTG2 transcription.